Regulatory-genome ncRNAs drive disease cell states
PrimaryHAYA's core causal theory is that non-coding RNAs in the regulatory genome are not merely biomarkers but causal controllers of pathological cell states. By using multimodal functional genomics and computational target discovery to identify disease-driving ncRNAs, programmable RNA medicines should be able to reprogram those cells away from disease-maintaining states and thereby alter chronic, age-related disease trajectories.
A testable prediction is that perturbing the selected ncRNA target should change the disease-state transcriptional or epigenomic program more effectively than targeting downstream marker genes, and this should translate into improved tissue-level disease phenotypes in relevant models.
company website · Tue Jun 30 2026 13:38:18 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility8.0
The premise is biologically credible. The strongest support is SEAL1: it is expressed in myCAF states across several cancer datasets, sits in disease-associated co-regulatory networks, and ASO perturbation reduces myCAF identity. That pattern fits a causal controller better than a passive marker. The weaker part is generalization. Evidence from cancer, cardiovascular, and mitochondrial ncRNA biology supports the class-level idea, but it does not yet prove that programmable RNA medicines can reliably reprogram chronic age-related disease states in human tissues.
Supporting evidence: SEAL1 is restrictively expressed in pan-cancer myofibroblast-like CAF states linked to poor prognosis and treatment response.; ASO targeting of SEAL1 or its murine functional analog reduces myCAF identity in cellular models.; Targeting LRRC15, a downstream marker of the myCAF state, does not reduce the disease-driving myCAF program.
Counter evidence: Much of the direct causal evidence centers on SEAL1 and myCAF biology, so the broader claim across chronic age-related diseases rests on extension rather than direct proof.; Delivery, specificity, potency, and durability of programmable RNA medicines in the relevant disease tissues remain assumptions.
Explanatory power7.0
The theory explains the SEAL1 evidence well. If SEAL1 helps control the myCAF regulatory program, then knocking it down should shift cell identity and reduce tumor-supporting behavior, while knocking down LRRC15 should fail because LRRC15 is downstream. That is exactly the reported pattern. Alternative explanations still exist: SEAL1 perturbation could have off-target ASO effects, model-specific effects, or reflect a cancer-fibroblast circuit that does not travel cleanly into other diseases. The theory has real explanatory bite, but one anchor example cannot carry the whole age-related disease claim by itself.
Supporting evidence: SEAL1 targeting reduces myCAF identity, while LRRC15 targeting by ASO or CRISPRi does not.; In a xenograft co-injection model, SEAL1 targeting in patient-derived myCAFs reduces tumor volume, while LRRC15 targeting does not.; SEAL1 appears in myCAF co-regulatory networks across breast, head and neck, and pancreatic cancer datasets.
Counter evidence: The evidence context does not show broad head-to-head tests across many ncRNA targets, cell states, and disease models.; Cardiovascular and mitochondrial ncRNA observations support relevance, but much of that evidence is associative or indirect.
Falsifiability9.0
This theory is highly testable. It predicts that perturbing a selected ncRNA should shift the disease-state transcriptional or epigenomic program more strongly than perturbing downstream marker genes, and that this molecular shift should improve tissue-level phenotypes in relevant models. Those are clear failure points. If selected ncRNAs repeatedly behave like markers, if downstream genes perform as well or better, or if cell-state changes fail to improve disease phenotypes, the theory takes a direct hit.
Supporting evidence: The stated prediction compares ncRNA perturbation against downstream marker-gene targeting.; The SEAL1 versus LRRC15 experiments already instantiate that comparison in myCAF models.; The theory also predicts tissue-level benefit, tested here by reduced tumor volume after SEAL1 targeting in a xenograft co-injection model.
Counter evidence: Some versions of the theory could be protected by arguing that each failed target was simply the wrong ncRNA, so target-selection rules need pre-specified thresholds.; Human therapeutic falsification remains harder because delivery and durability can fail even if the ncRNA biology is right.
Reasoning tree
premiseNon-coding RNAs in the regulatory genome can act as causal controllers of pathological cell states rather than merely as biomarkers.
high confidence - 3 linked evidence items
premiseimplies
Regulatory lncRNAs can be highly cell-state-specific and disease-specific, making them candidates for disease-state control points.
high confidence - 2 linked evidence items
observationobserved_in
SEAL1 is restrictively expressed in pan-cancer myofibroblast-like CAF cell states associated with poor prognosis and treatment response.
high confidence - 1 linked evidence item
observationobserved_in
SEAL1 appears as a key component of disease-driving myCAF co-regulatory networks across breast, head and neck, and pancreatic cancer datasets.
high confidence - 1 linked evidence item
observationobserved_in
ASO-mediated targeting of SEAL1 or its murine functional analog reduces myCAF identity in cellular models.
high confidence - 1 linked evidence item
observationobserved_in
Targeting LRRC15, a downstream marker of the myCAF state, by ASO or CRISPRi does not reduce the disease-driving myCAF cell state.
high confidence - 1 linked evidence item
observationobserved_in
In a xenograft co-injection model, SEAL1 targeting in patient-derived myCAFs reduces tumor volume, while LRRC15 targeting does not.
high confidence - 1 linked evidence item
derivationimplies
Disease-state regulatory ncRNAs can be more effective therapeutic targets than downstream marker genes because they sit closer to causal control of the pathological program.
high confidence - 1 linked evidence item
derivationimplies
If causal ncRNA controllers of pathological cell states are identified, programmable RNA medicines should be able to perturb those targets and reprogram cells away from disease-maintaining states.
medium confidence - 1 linked evidence item
project_implicationimplies
HAYA should prioritize discovery and validation of regulatory-genome ncRNA targets that causally control disease cell-state programs, rather than prioritizing downstream marker genes alone.
high confidence - 1 linked evidence item
predictionpredicts
Perturbing a selected disease-driving ncRNA target should change the disease-state transcriptional or epigenomic program more effectively than targeting downstream marker genes.
high confidence - 1 linked evidence item
predictionpredicts
Effective perturbation of a disease-driving ncRNA should translate into improved tissue-level disease phenotypes in relevant disease models.
high confidence - 1 linked evidence item
project_implicationimplies
Successful validation would support a therapeutic strategy aimed at altering chronic, age-related disease trajectories by reprogramming disease-maintaining cell states through ncRNA perturbation.
medium confidence - 3 linked evidence items
assumptionassumes
Programmable RNA medicines can achieve sufficient delivery, specificity, potency, and durability in the relevant disease tissues to reprogram pathological cell states therapeutically.
medium confidence - 1 linked evidence item
premiserequires
Multimodal functional genomics and computational target discovery can identify ncRNAs that drive disease-maintaining cell states.
medium confidence - 3 linked evidence items
assumptionassumes
Expression specificity, network centrality, and perturbation response are sufficient evidence to prioritize an ncRNA as a disease-driving target.
medium confidence - 1 linked evidence item
assumptionassumes
Functional regulatory roles observed for ncRNAs in cancer and cardiovascular disease models generalize to other chronic age-related diseases where pathological cell states maintain disease progression.
medium confidence - 3 linked evidence items
observationobserved_in
Mitochondrial noncoding RNAs participate in nucleus-mitochondria communication and are implicated in physiological and pathological conditions relevant to cardiovascular and neurological disease.
medium confidence - 1 linked evidence item
observationobserved_in
Cardiac-enriched or disease-differential lncRNAs can distinguish cardiovascular conditions such as myocarditis and acute myocardial infarction in blood samples.
medium confidence - 1 linked evidence item
observationobserved_in
PDGF-AB treatment after myocardial infarction alters transcript variants and long noncoding RNA expression while reducing myofibroblast differentiation and improving scar-related remodeling features.
medium confidence - 1 linked evidence item
Public endorsements
silent
The dossier shows Daniel Blessing is HAYA's co-founder/CTO and that he led HTX-001 development, but it does not contain a public statement from him on the theory that regulatory-genome ncRNAs causally drive disease cell states. His only direct quote here is "The team is the key!", which does not address the scientific claim.
mentions
Le Temps appears in the dossier as the outlet behind coverage of HAYA Therapeutics, including an article and podcast about the company. That is a public mention of HAYA, but the provided evidence does not show Le Temps explicitly endorsing or disputing the specific theory that regulatory-genome ncRNAs causally drive disease cell states.
Evidence publication IDs: 35a496e6-de93-4684-9e07-58bc76f4b22d, 6d90ef38-52a6-4cda-96db-ce1b4cc73e67
silent
No public quotes, records, or publications are provided for Mihaela Roberts on this theory. With no evidence tying her to a public statement, the defensible classification is silence.
publicly endorses
Ounzain does more than mention this theory, he states it as HAYA's scientific basis. The dossier ties him to founding HAYA around cell reprogramming via the regulatory genome, quotes him on expanding a regulatory-genome targeting platform, and describes him as an early researcher arguing that lncRNAs control genes, cells, and disease states. The 2025 interviews also frame HAYA around the dark genome, disease links, and treating disease through ncRNA biology. That is a public endorsement of the core causal claim, not a neutral reference.
Evidence publication IDs: aae018a2-af4d-4d9b-bd66-f96c01f7d353, b4cc7fc4-737e-45d8-97c3-6639205ee72b
silent
The record identifies Daniel Blessing as HAYA's CTO and co-founder, but the supplied public theory statements come from Samir Ounzain's interviews and video descriptions, not from Blessing himself. On this evidence, Blessing is publicly silent on the theory.
Regulatory lncRNAs reprogram disease-driving cell states
PrimaryHAYA's central causal theory is that non-coding RNAs in the regulatory genome are not merely disease markers but causal controllers of pathological cell states. By identifying disease-specific regulatory lncRNAs with functional genomics and computational tools, programmable RNA medicines can modulate those RNAs and reprogram cells away from disease-driving states toward healthier states.
A testable prediction is that perturbing a causal lncRNA will change the underlying disease-cell transcriptional program, while perturbing downstream marker genes alone may not reproduce the same state change. In age-related chronic diseases such as cardiovascular fibrosis, cancer, and metabolic disease, this should reduce pathological remodeling, improve tissue function, or improve response to existing therapies.
company website · Sun Jun 14 2026 03:11:33 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility8.0
The premise is credible: lncRNAs can regulate epigenomic and transcriptomic programs, and the SEAL1 case gives a concrete causal example in myofibroblast-like cancer-associated fibroblasts. The theory is strongest where it claims that some disease-specific lncRNAs can control cell state. It is weaker when it generalizes across cardiovascular fibrosis, cancer, and metabolic disease, because the supplied cardiovascular evidence is mostly expression and association, with less direct perturbation data.
Supporting evidence: SEAL1 is restrictively expressed in pan-cancer myCAF states linked to poor prognosis and treatment response.; Independent breast, head and neck, and pancreatic cancer datasets place SEAL1 inside disease-driving myCAF co-regulatory networks.; ASO targeting of SEAL1 or its murine functional analog reduced myCAF identity in cellular models.
Counter evidence: Cardiovascular examples show lncRNA expression changes and disease-associated panels, but they do not yet show that the named lncRNAs are causal controllers.; The theory assumes causal lncRNAs will be accessible, specific, and modifiable enough for RNA medicines without unacceptable off-target effects. That is plausible, but still a working assumption.
Mitochondrial RNAs regulate disease-relevant metabolism and signaling
The mitochondrial RNA publication frames a broader mechanistic theory relevant to HAYA's non-coding RNA focus: mitochondrial coding and non-coding RNAs participate in nucleus-mitochondria communication and influence metabolism and signaling in high-energy tissues such as cardiomyocytes, hepatocytes, and neurons. Because mitochondrial dysfunction is implicated in cardiovascular and neurological disease, systematic functional analysis of mitochondrial RNAs could uncover therapeutic targets for age-related tissue decline.
The testable prediction is that standardized profiling and perturbation of mitochondrial RNAs will identify reproducible RNA regulators whose modulation changes mitochondrial signaling, cellular metabolism, or disease phenotypes in relevant cardiovascular or neurological models.
publication · Tue Jun 30 2026 13:38:19 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility7.0
The premises are credible: mitochondria control metabolism and signaling, mitochondrial RNAs include several coding and non-coding classes, and high-energy tissues are sensible places to look. The weak point is causal reach. The evidence supports mitochondrial RNAs as biologically relevant and disease-associated, but it does not yet prove that many of them drive cardiovascular or neurological phenotypes when perturbed.
Supporting evidence: Mitochondrial coding and non-coding RNAs are described as regulators in mammalian cells, with mitochondria central to metabolism and signaling.; Mitochondrial RNAs participate in anterograde and retrograde communication between the nucleus and mitochondria.; Cardiomyocytes, hepatocytes, and neurons are high-energy tissues where mitochondrial regulation is especially relevant.; Cardiovascular and neurological diseases involve high-energy-consuming cells and pathological mitochondrial regulation.
Counter evidence: Current mitochondrial RNA research lacks standardized protocols for deep functional characterization and expression profiling.; The theory depends on the assumption that disease-relevant mitochondrial RNA regulators will be detectable and functionally perturbable in cardiovascular or neurological models.; Some support comes from broader lncRNA disease biology, which strengthens plausibility but does not prove mitochondrial RNA causality.
Cardiac lncRNA signatures report disease state
The FIMICS work supports a diagnostic and monitoring theory: cardiac-enriched and disease-associated long non-coding RNAs reflect cardiovascular pathological states and can be measured to distinguish disease contexts such as myocarditis and acute myocardial infarction. The causal therapeutic claim is weaker here, but the mechanistic premise is that lncRNA expression is tightly linked to heart-specific disease biology and therefore can reveal, stratify, or track age-related cardiovascular disease processes.
A testable prediction is that defined lncRNA panels should reproducibly separate failing from non-failing hearts or distinguish cardiovascular disease states in blood, and changes in these lncRNAs may track disease progression or therapeutic response.
publication · Tue Jun 30 2026 13:38:19 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility8.0
The premise is credible: FIMICS reports 2906 cardiac-enriched or disease-associated lncRNAs, and selected blood lncRNAs separated myocarditis from acute myocardial infarction. That supports a biomarker theory. The stronger claim, that these RNAs are stable and specific enough for routine monitoring, still needs standardized measurement and external validation.
Supporting evidence: FIMICS identified 2906 lncRNAs that were cardiac-enriched or differentially expressed between failing and non-failing hearts.; Selected lncRNAs measured in blood differentiated myocarditis from acute myocardial infarction.; After myocardial infarction, PDGF-AB treatment altered lncRNA expression in cardiac tissue pathways linked to cell cycle and scar maturation.
Counter evidence: The evidence base still depends on the assumption that measured lncRNA abundance is stable, specific, and reproducible across tissue, blood, platforms, and cohorts.; Guidelines for mitochondrial RNA analysis state that noncoding RNA profiling lacks standardized protocols, which can create variability between studies.
SEAL1 maintains pro-tumorigenic myCAF identity
The SEAL1 program's causal theory is that the long non-coding RNA SEAL1 is a key regulator of the myofibroblast-like cancer-associated fibroblast state, which contributes to extracellular-matrix dysregulation, immune suppression, treatment resistance, metastasis, and poor prognosis in solid tumors. Targeting SEAL1 with antisense oligonucleotides should reduce the disease-driving myCAF identity and make the tumor microenvironment less supportive of tumor growth and therapy resistance.
This theory predicts that SEAL1 inhibition will collapse myCAF transcriptional programs, while inhibition of downstream markers such as LRRC15 will not be sufficient. The supplied abstract reports exactly that pattern in vitro and further reports reduced tumor volume after SEAL1 targeting in a xenograft co-injection model.
publication · Tue Jun 30 2026 13:38:18 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility7.0
The starting premise is credible: myCAFs are linked to ECM dysregulation, immune suppression, treatment resistance, metastasis, and poor prognosis, and SEAL1 is reported as restrictively expressed in the pan-cancer myCAF state. The causal step is plausible because lncRNAs can regulate transcriptomic and epigenomic programs, but the case still depends on one abstract and model systems. The weak point is translation: ASO delivery, specificity, durability, and safety in solid tumors remain open.
Supporting evidence: SEAL1 is reported as restrictively expressed in the pan-cancer myCAF cell state and associated with poor prognosis and treatment response.; Independent analyses of breast, head and neck, and pancreatic cancer datasets identify SEAL1 in disease-driving myCAF co-regulatory networks.; ASO-mediated targeting of SEAL1 and murine Seal1 reduced myCAF identity in cellular models.
Counter evidence: The supplied evidence comes from an abstract, with limited methodological detail.; The therapeutic premise requires ASO delivery to fibroblast states inside solid tumors, and that assumption has low confidence.; Clinical myCAF biology may be only partly captured by the in vitro and xenograft co-injection models.
Reprogramming cardiac fibroblasts can reduce fibrosis
For cardiac fibrosis, HAYA's implied mechanism is that pathological remodeling after cardiac injury is sustained by disease-driving fibroblast or myofibroblast cell states that can be controlled through regulatory-genome RNA targets. HTX-001 is presented as an RNA-guided program for cardiac fibrosis intended to reprogram those disease-driving cell states rather than simply block a single downstream fibrosis marker.
The testable prediction is that RNA-guided modulation of the relevant non-coding RNA program should reduce fibrotic remodeling, improve scar or tissue organization, and preserve or improve cardiac function in cardiomyopathy or post-injury heart models.
company website · Tue Jun 30 2026 13:38:18 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility7.0
The premises are credible. Cardiac injury can push fibroblasts into myofibroblast states, and those states can shape fibrosis, scar remodeling, and function. Regulatory RNAs also have a real basis as cell-state regulators. The weak link is causal specificity: the evidence says cardiac lncRNA programs track disease, but it does not yet prove that HTX-001's chosen RNA targets drive cardiac fibrosis rather than mark it.
Supporting evidence: Fibroblasts can transition into myofibroblast states after myocardial infarction, contributing to fibrosis and scar remodeling.; Cardiac-enriched and heart-failure-associated lncRNAs can distinguish cardiovascular disease states.; RNA-chromatin interactions give a plausible route by which regulatory RNAs can alter gene-expression programs.
Counter evidence: The strongest target-intervention evidence comes from cancer-associated myofibroblast-like fibroblasts, not cardiac fibroblasts.; The theory assumes the relevant cardiac non-coding RNAs are causal regulators, but the supplied evidence mostly supports disease association.
Explanatory power6.0
The theory explains why blocking one downstream fibrosis marker may fail: a disease-driving fibroblast state can keep the broader program alive. That is a useful mechanistic explanation. Still, it has not yet beaten simpler explanations such as general anti-inflammatory effects, altered injury severity, improved hemodynamics, or broad transcriptional disruption after RNA modulation.
Cardiac-enriched lncRNAs reflect and stratify age-related cardiovascular pathology
The FIMICS work supports the theory that cardiac-enriched and heart-failure-associated lncRNAs capture disease-relevant regulatory states in cardiovascular disorders. Because lncRNAs are highly tissue- and disease-state-specific, their expression patterns can reveal pathological cardiac remodeling and distinguish related cardiovascular conditions.
A testable prediction is that selected lncRNA panels should differentiate patients with distinct cardiovascular pathologies, support diagnosis or prognosis, and potentially identify regulatory programs suitable for therapeutic intervention. The cited study reports that lncRNA expression in blood differentiated myocarditis and acute myocardial infarction patients.
publication · Sun Jun 14 2026 03:11:33 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility8.0
The premise is credible: lncRNAs are often tissue-specific, disease-state-specific, and plausible reporters of cardiac remodeling. FIMICS gives the theory a concrete base by identifying 2906 cardiac-enriched or heart-failure-associated lncRNAs. The weak point is blood. A cardiac signal measured in blood can be real, but it can also be diluted by immune-cell composition, injury response, medication, and sampling effects.
Supporting evidence: FIMICS identified 2906 lncRNAs that were cardiac-enriched or differentially expressed between failing and non-failing hearts.; The cited study reports that blood lncRNA expression differentiated myocarditis from acute myocardial infarction.; The evidence context states that lncRNAs are highly tissue-specific and can function as biomarkers in human disease.
Counter evidence: Blood-measured lncRNA expression requires the assumption that enough cardiac disease signal survives outside the heart.; The mitochondrial RNA guideline paper warns that RNA profiling still has standardization and reproducibility problems.
SEAL1 drives pro-tumorigenic myCAF identity
The SEAL1 program proposes that the lncRNA SEAL1 is a causal regulator of the myofibroblast-like cancer-associated fibroblast cell state, a desmoplastic and immunosuppressive stromal state associated with poor prognosis, treatment resistance, metastasis, and immunotherapy failure in solid tumors. The therapeutic mechanism is that ASO-mediated SEAL1 inhibition reduces the myCAF identity and thereby weakens tumor-supportive stromal programs.
A testable prediction is that SEAL1 targeting should reduce myCAF transcriptional identity and tumor-supportive extracellular matrix or immune-suppressive features, whereas targeting a downstream myCAF marker such as LRRC15 may fail to change the causal cell state. The provided abstract reports this pattern in vitro and in a xenograft co-injection model, where SEAL1 targeting reduced tumor volume while LRRC15 targeting did not.
publication · Sun Jun 14 2026 03:11:33 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility7.0
The premise is credible: myCAFs are already described here as a desmoplastic, immune-suppressive stromal state linked to poor prognosis, treatment resistance, metastasis, and immunotherapy failure, and SEAL1 is reported as selectively expressed in that state. The causal jump is still the weak point. A lncRNA can regulate cell-state programs, but the supplied evidence comes from an abstract, in vitro models, and one xenograft co-injection model, so we should treat SEAL1 as a plausible upstream regulator rather than a settled driver.
Supporting evidence: SEAL1 is reported as restrictively expressed in the pan-cancer myCAF cell state.; Independent breast, head and neck, and pancreatic cancer dataset analyses place SEAL1 in myCAF co-regulatory networks.; ASO-mediated SEAL1 or Seal1 targeting reduced myCAF identity in cellular models.
Counter evidence: The causal claim relies on abstract-level evidence, with no detailed dose response, rescue experiment, mechanism, or independent replication provided here.; Association with poor prognosis and treatment response does not by itself prove SEAL1 maintains the myCAF state.
HTX-001 targets cardiac fibrosis by reprogramming fibrotic cell states
HAYA's HTX-001 program is based on the claim that cardiac fibrosis is maintained by disease-driving cell states that can be therapeutically reprogrammed with RNA-guided medicines. The implied mechanism is that targeting causal regulatory RNA programs in fibrotic cardiac cells should reduce maladaptive fibrosis rather than only treating downstream symptoms of cardiomyopathy or heart failure.
A testable prediction is that HTX-001 should shift cardiac fibroblast or fibrosis-associated transcriptional states toward less pathological profiles, leading to reduced fibrosis burden, improved scar or tissue remodeling, and better cardiac function in preclinical or clinical cardiomyopathy settings.
company website · Sun Jun 14 2026 03:11:33 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility7.0
The starting premise is credible: cardiac fibrosis involves fibroblast and myofibroblast states, and regulatory RNAs can shape transcriptional programs. The weak point is delivery and causality. HTX-001 needs its RNA targets to drive the fibrotic cardiac state in vivo, and the evidence provided does not yet show that for HTX-001 itself.
Supporting evidence: PDGF-AB treatment reduced cardiac fibroblast myofibroblast differentiation, changed transcript and lncRNA expression after myocardial infarction, accelerated scar formation, and improved remodeling without increasing fibrosis.; SEAL1 targeting reduced myCAF identity in cancer-associated fibroblasts, while targeting the downstream marker LRRC15 did not alter that disease-driving state.; Cardiac-enriched or heart-failure-associated lncRNAs can distinguish cardiovascular pathological states.
Counter evidence: The strongest direct RNA-targeting example comes from cancer-associated fibroblasts, not cardiac fibrosis.; The evidence context marks sufficient exposure and specificity in fibrotic cardiac cells as low confidence.; Disease-associated RNA expression can be a biomarker rather than a causal regulator.
